Drug Profile
Research programme: protein therapeutics - Protelica
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Protelica
- Class Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 21 Jan 2009 Preclinical trials in Cancer in USA (unspecified route)